Junior Accountant
- Employer
- Scilex Holding Company
- Location
- Palo Alto, CA
- Start date
- Oct 3, 2024
View more categoriesView less categories
- Discipline
- Administration, Accounting
- Required Education
- Bachelors Degree
- Position Type
- Full time
- Hotbed
- Biotech Bay
Job Details
Salary Range: $60,000.00 - $70,000.00
The pay range for this position is expected to be between $60,000 - $70,000/annually.
Job Type: Contract-to-Permanent Duration: 3-6 Months (with the possibility of becoming a permanent position) Hybrid position: 3 days on-site, 2 days remote We are seeking a Junior Accountant to join our team on a contract basis with the potential to transition to a permanent role after 3-6 months. This position offers an excellent opportunity for career growth and development within our company. The position is eligible to participate in the Company's comprehensive benefits, which includes Flexible PTO, company paid holidays, life and AD&D, long-term disability, flexible reimbursement plan and Medical, dental, vision insurance coverage.If hired, employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other payment or compensation program) at any time, including reasons related to individual performance, Company or individual department/team performance, and market factors.
Scilex Holding Company’s pay range data is provided in accordance with local state pay transparency regulations. Scilex Holding Company may post different minimum wage ranges for permanent residency petitions pursuant to US Department of Labor requirements.
Scilex Holding Company is committed to equal employment opportunities, and a workplace that embraces diversity and inclusion for qualified individuals of all backgrounds.
About Scilex
SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.
The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. Click here for ZTLido’s Important Safety Information and US Prescribing Information.
We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYBTM, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. We launched ELYXYBTM in the U.S. in April 2023 and launched GLOPERBA in 2024.
Our three product candidates are (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXATM”), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica and has received Fast Track Status from the FDA. Currently there is no FDA approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain (“LBP”) and has received Fast Track Status from the FDA; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States.
SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most. Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.
If you’re a high-energy, compassionate, and collaborative individual with a strong desire to make a difference in patient’s lives, we encourage you to consider joining the Scilex Holding team!
Role and Responsibilities
- Maintain accounts receivable records to ensure aging is up to date, credits and collections are applied, uncollectible amounts are accounted for, and miscellaneous differences are cleared.
- Maintain and reconcile customer accounts, set up new customers, and credit limit.
- Perform daily cash management duties, including the recording of bank deposits, wire/ACH payments, and posting of cash to the AR sub-ledger.
- Monitor and collect accounts receivable by contacting customers via telephone and email.
- Download gross sales report from 3PL system and import it to NetSuite using csv import.
- Prepare invoices and AR payment deductions journal entries for chargeback, chargeback rejection, return and service fees.
- Prepare AR weekly reports.
- Prepare monthly inventory adjustments and inventory accounts reconciliation.
- Analyzes, researches, and reconciles past payments.
- Maintains and reconciles A/R aging reports, check registers, and A/R journals.
- Responsible for Accounts Receivable month-end close procedures such as cash discounts and credit card fees journal entries.
- Prepare journal entries, account reconciliations and fluxes as part of month/quarter/year end reporting.
- Assist Management with various special projects and ad hoc reporting.
- Assists with preparation of documentation for the annual audit.
Qualifications and Education Requirements
- Bachelor’s degree in accounting.
- Knowledge of General Accepted Accounting Principles (GAAP).
- Proficient in Microsoft Outlook, Word and Excel.
- Knowledge of automated financial systems.
Preferred Skills
- Demonstrated written and verbal communication.
- Knowledge of automated financial systems.
- Strong integrity and professionalism.
- Good judgment and experience in solving problems.
- Ability to contribute to and work within a cross-functional team.
- Ability to work effectively in a fast-paced environment with multiple deadlines and frequently changing priorities.
- Must possess the ability to take initiative to complete assignments and job responsibilities with minimal supervision.
- Highly organized with a strong attention to detail, clarity, accuracy, and conciseness.
- Proficient in bill.com, Concur, preferred NetSuite or other ERP.
Company
SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), majority-owned by Sorrento, is dedicated to the development and commercialization of non-opioid pain management products. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.
The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a branded prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain.
Scilex’s SP-102 (10 mg dexamethasone sodium phosphate viscous gel injection), or SEMDEXA™, for the treatment of Lumbar Radicular Pain has completed enrollment in a Phase III clinical trial and has received Fast Track Status from the FDA. If approved by the FDA, the company expects SP-102 to be the first FDA-approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica, with the potential to replace 10 to 11 million off-label epidural steroid injections administered each year in the US.
SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most.
Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.
- Website
- https://www.scilexholding.com/
- Phone
- (650) 516-4310
- Location
-
960 San Antonio Road
Palo Alto
California
94303
US
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert